Partner Michael Blau is quoted in an OncologyLive article, “The Looming Squeeze on Provider Returns,” about legislative and policy changes that are affecting the prospects for independent oncology practices and the ability of inner-city and charity-care hospitals to continue serving low-income residents.
Blau, who moderated a panel of experts at the 2018 Association of Community Cancer Centers’ 44th Annual Meeting and Cancer Center Business Summit, said that many hospital acquisitions and alignments have been driven by shared-service agreements and co-management arrangements that allowed increased returns of up to 15 percent. But such margins will be much slimmer going forward, he said, and some financial “downside” can be expected.
Blau, who moderated a panel of experts at the 2018 Association of Community Cancer Centers’ 44th Annual Meeting and Cancer Center Business Summit, said that many hospital acquisitions and alignments have been driven by shared-service agreements and co-management arrangements that allowed increased returns of up to 15 percent. But such margins will be much slimmer going forward, he said, and some financial “downside” can be expected.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”